No Data
No Data
No Data
No Data
No Data
Cube Pharmaceuticals (003020): Divestment of Cube Pharmaceuticals' Q1 performance continues to push forward R&D under apparent pressure
Incident: The company released its report for the first quarter of 2024. 2024Q1 achieved revenue of 334 million yuan (-58.90%), net profit to mother of 30 million yuan (-54.08% year over year), deducted from non-return to mother
信達證券May 1 00:00
Cube Pharmaceuticals (003020.SZ) reported first-quarter results, net profit of 30.3722 million yuan, a year-on-year decrease of 54.08%
Cube Pharmaceuticals (003020.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Zhitong FinanceApr 29 20:01
Cube Pharmaceuticals (003020): Divestment of commercial business affects revenue, increases R&D investment and lays out the future
Cube Pharmaceutical announced its 2023 annual report and 2024 quarterly report. The company achieved operating income of 1,901 billion yuan in 2023, -26.3% year over year; net profit to mother was 227 million yuan, +8.3% year over year; deducted
招商證券Apr 29 00:00
Express News | Cube Pharmaceuticals: Received a notice of approval for the marketing application of the API nifedipine
BreakingsApr 26 16:25
Cube Pharmaceuticals (003020.SZ) announced its 2023 annual results, with net profit of 227 million yuan, an increase of 8.33%
Cube Pharmaceutical (003020.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 1...
Zhitong FinanceApr 22 20:44
Express News | Cube Pharmaceuticals: Mesalazine Enteric Tablet Drug Registration and Marketing License Application Accepted
BreakingsFeb 26 19:18
No Data
No Data